^
Association details:
| Biomarker: | DSPP mutation + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
Published date:
10/15/2021
Excerpt:
The double mutations of DSPP and TP53 (DT) were the most effective combination after screening, which were associated with significantly longer median PFS than wild type (9.3 versus 4.9 months, P = 0.008; Fig. 3c)….DSPP mutation might serve as a potential biomarker for this combination.
Secondary therapy:
carboplatin + pemetrexed
DOI:
https://doi.org/10.1038/s41392-021-00751-9
Trial ID:
